Francisco Navarro

Francisco Navarro has over 25 years of experience in the scientific field. Francisco began their career in 1995 as a Graduate Student at the Universidad Autónoma de Madrid. Francisco then moved to the Salk Institute for Biological Studies in 2001 as a Postdoctoral Research Fellow. In 2004, they joined Harvard Medical School as an Instructor in Pediatrics and a Postdoctoral Research Fellow, where they conducted research on the role of microRNAs in regulating hematopoiesis and the role of miR-34a in the p53 tumor suppressor network. In 2014, Navarro became a Scientist at Rubius Therapeutics. Francisco then moved to NantKwest in 2015 as a Scientist III, Immunotherapy. In 2018, they joined bluebird bio as a Scientist II, Immunotherapy & Gene Editing. In 2020, Navarro became a Senior Scientist, Immunotherapy & Gene Editing at ElevateBio. Most recently, in 2021, they joined SalioGen Therapeutics as a Principal Scientist, Cell Therapy.

Francisco Navarro holds a Doctor of Philosophy (PhD) in Immunology from the Universidad Autónoma de Madrid and a Bachelor's degree in Biological Sciences from the Universidad Complutense de Madrid.